News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Rohan Garje: Avelumab and taxol chemotherapy in platinum-refractory or ineligible metastatic urothelial carcinoma
baptisthealth.net
Jun 9, 2025, 04:36

Rohan Garje: Avelumab and taxol chemotherapy in platinum-refractory or ineligible metastatic urothelial carcinoma

Rohan Garje, Associate Professor, Chief of Genitourinary Medical Oncology at Miami Cancer Institute, shared a post on LinkedIn:

“Proud to share our latest investigator-initiated trial! 
Thrilled to author our new paper: “Avelumab and taxol chemotherapy in platinum-refractory or ineligible metastatic urothelial carcinoma (AVETAX trial)” 
 Safe combo of avelumab + docetaxel
 ORR: 52.4% response rate in a platinum-refractory/ineligible group
 Median PFS: 14.6 mo | OS: 16.6 mo
Though the current landscape of bladder cancer has changed with frontline EV + Pembrolizumab, this could be a potential option for further evaluation
Grateful to all my amazing co-authors and a special thanks to Dr. Yousef Zakharia for his mentorship. Great work by Aditya Ravindra, hemo onc fellow University of Iowa rising star in oncology.”

Title: Avelumab and taxol chemotherapy in platinum-refractory or ineligible metastatic urothelial carcinoma (AVETAX trial)

Authors: Rohan Garje, Aditya Ravindra, Bilal Rahim, Mathew Kroll, Jeffrey S. Johnson, Julie Torres, Jaime Bonner, Vignesh T. Packiam, Sarah Mott, Michael O’Donnell, Yousef Zakharia

Read the Full Article.

Rohan Garje

More posts featuring Rohan Garje.

Aditya Ravindra AVETAX trial Bilal Rahim cancer Jaime Bonner Jeffrey S. Johnson Julie Torres Mathew Kroll Michael O’Donnell OncoDaily Oncology Rohan Garje Sarah Mott Vignesh T. Packiam Yousef Zakharia
Special Coverage
Insight
Jun 9, 2025, 04:36
Rohan Garje: Avelumab and taxol chemotherapy in platinum-refractory or ineligible metastatic urothelial carcinoma
Blog
Jun 9, 2025, 04:15
Herdee Luna: How Precision Medicine is Changing the Game for Rare RET Fusion
Blog
Jun 9, 2025, 04:06
Fumiko Ladd Chino Reflects on Resilience Through Patient’s Gift
Blog
Jun 9, 2025, 03:59
UICC opens the 2025 Technical Fellowships call for Applications
Blog
Jun 9, 2025, 03:26
Al-Ola A Abdallah: Countdown Begins for the National ICE-T Conference
Blog
Jun 9, 2025, 03:08
Last Chance to Apply: AI in Cancer Research Summer School 2025 in Corfu
Blog
Jun 9, 2025, 02:00
Irena Joveva: Health has no borders, and silence is not an option
Blog
Jun 9, 2025, 01:16
Wafik S. El-Deiry: Leading Discussions of our Legorreta Cancer Center Research Program Leaders
Oncolibrary
Jun 8, 2025, 17:28
ASCO 2025 Plenary Highlights: Key Practice-Changing Data Across TOP 5 ATOMIC, MATTERHORN, SERENA-6, VERIFY, and NIVOPOSTOP Trials
Blog
Jun 8, 2025, 17:04
Kimryn Rathmell Highlighted BuckeyeThon Students Raising Pediatric Blood Cancer Awareness at Farmers Market
Career
Jun 8, 2025, 17:03
Herbert Loong Joined IASLC Communications Committee For the 2025-2027 Term
Insight
Jun 8, 2025, 17:00
Christian Rolfo Highlighted VISION Trial Findings on METex14 NSCLC Detection Using Liquid and Tissue Biopsies